Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing surgery-related mortality and morbidity

  • Protocol
  • Intervention

Authors

  • Zui Zou,

    1. Changzheng Hospital, The Second Military Medical University, Department of Anaesthesiology, Shanghai, Shanghai, China
    Search for more papers by this author
  • Hong B Yuan,

    1. Changzheng Hospital, The Second Military Medical University, Department of Anaesthesiology, Shanghai, Shanghai, China
    Search for more papers by this author
  • Xiao Y Chen,

    1. The General Hospital of the People's Liberation Army (PLAGH) (also Hospital 301), Department of Neurology, Beijing, Beijing, China
    Search for more papers by this author
  • Guan J Liu,

    1. West China Hospital, Sichuan University, Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, Chengdu, Sichuan, China
    Search for more papers by this author
  • Xue Y Shi

    Corresponding author
    1. Changzheng Hospital, The Second Military Medical University, Department of Anaesthesiology, Shanghai, Shanghai, China
    • Xue Y Shi, Department of Anaesthesiology, Changzheng Hospital, The Second Military Medical University, No 415, Feng Yang Road, Shanghai, Shanghai, 200003, China. shixueyin1128@yahoo.com.cn.

    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objective of this review is to systematically assess the benefits and harms of administration (prophylaxis or treatment or both) of Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type I receptors blockers (ARBs) in the short-term perioperative period for the prevention of surgery related mortality and morbidity.